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Current clinical guidelines for the management of radiotherapy patients having either a pacemaker or implantable
cardioverter defibrillator (both CIEDs: Cardiac Implantable Electronic Devices) do not cover modern radiotherapy
techniques and do not take the patient’s perspective into account. Available data on the frequency and cause of
CIED failure during radiation therapy are limited and do not converge. The Dutch Society of Radiotherapy and
Oncology (NVRO) initiated a multidisciplinary task group consisting of clinical physicists, cardiologists, radiation
oncologists, pacemaker and ICD technologists to develop evidence based consensus guidelines for the
management of CIED patients. CIED patients receiving radiotherapy should be categorised based on the chance of
device failure and the clinical consequences in case of failure. Although there is no clear cut-off point nor a clear
linear relationship, in general, chances of device failure increase with increasing doses. Clinical consequences of
device failures like loss of pacing, carry the most risks in pacing dependent patients. Cumulative dose and pacing
dependency have been combined to categorise patients into low, medium and high risk groups. Patients receiving
a dose of less than 2 Gy to their CIED are categorised as low risk, unless pacing dependent since then they are
medium risk. Between 2 and 10 Gy, all patients are categorised as medium risk, while above 10 Gy every patient is
categorised as high risk. Measures to secure patient safety are described for each category. This guideline for the
management of CIED patients receiving radiotherapy takes into account modern radiotherapy techniques, CIED
technology, the patients’ perspective and the practical aspects necessary for the safe management of these
patients. The guideline is implemented in The Netherlands in 2012 and is expected to find clinical acceptance
outside The Netherlands as well.
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Pacemakers and ICDs may sustain damage during a
course of radiation therapy. ICDs are devices that in-
corporate pacemaker functionality as well as the ability
of producing a high voltage shock to terminate poten-
tially lethal cardiac arrhythmias. Pacemaker and ICDs
together are called Cardiac Implantable Electronic
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reproduction in any medium, provided the orpatients receiving radiotherapy with a CIED [1-10] are
not widely implemented [2,11]. The most cited guideline
is the AAPM guideline originating from 1994 [10]. Since
then, radiation therapy and CIED technology have chan-
ged significantly whereas the number CIEDs implanted
and the number of patients receiving radiotherapy have
increased tremendously. Radiation therapy is shifting
from the use of primarily conventional techniques and
conventional fractionations to IMRT and arc techniques
and the use of more hypofractionated schedules. The
higher fraction dose might lead to a potentially higher
dose per fraction to a CIED. However, the use of more
modern techniques has led to a reduced use of high en-
ergy photon beams, potentially leading to less dose to aral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ciplinary evidence based practice guidelines for the man-
agement of patients receiving radiotherapy with CIEDs.
Methods and materials
A multidisciplinary task group was organised to develop
an evidence based guideline for the management of
patients receiving radiotherapy with CIEDs. Major radi-
ation modalities were taken into account; external pho-
ton and electron beams (up to 21 MeV). 60Co beams
were not considered as they are not used anymore in
The Netherlands. Also orthovoltage beams are seldom
used in The Netherlands and if used outside the thoracic
region, these were considered not to pose any problems.
Electron beams at this energy or lower actually present a
smaller problem than photon beams, as the neutrons
production in these beams is much lower and neutrons
actually seem to generate the majority of CIED defects.
Electron therapy produces only 5% (at 15 MeV; [12]) to
20% (at 25 MeV; [13]) of the neutron dose equivalent
per gray as photon therapy at the same nominal energy.
This guideline is also applicable to patients receiving
gamma-ray brachytherapy. Due to the rapid dose fall-off
of this modality the CIED dose will generally be small.
The lower energy spectrum of gamma brachytherapy
implies a larger relative contribution of the photo-
electric effect due to high Z materials in the CIED,
and thus a localized higher dose to the CIED might
be anticipated than the usually reported dose to water
in surrounding tissue. However, as reports about
brachytherapy use in this patient population did not
reports any CIED problems yet, it was considered that
this treatment modality could be handled equivalent to
external beam photon therapy until more data will be-
come available in the literature [14,15]. The specific in-
fluence of imaging techniques like CT, EPID and CBCT
on CIED dose have not been described in detail within
this guideline. Generally, the dose from these imaging
techniques will be low. For example, Diederich et al. in-
dicate an axial air kerma _CTDIair_ of 30–50 mGy for a
typical multislice chest CT of an adult of average size
[16]. For 4D-CT scans, the dose is typically in the order
of 0.1-0.4 Gy while the dose from a kV-CBCT scan is
typically much lower (10–80 mGy) [17]. The literature
was first searched for guidelines and systematic reviews
in the Cochrane Library and through SUMsearch.
Thereafter, a Medline (OVID) search was conducted,
which produced articles that were referenced in the pre-
viously found literature. This search was performed in
May 2010, combining search terms “radiotherapy” or
“radiation therapy” with “ICD” or “pacemaker” or “car-
diac defibrillator”.
However, some more recent articles Based on this lit-
erature, the Dutch guideline was written. This article is asummary of the Dutch guideline which can be found at:
http://www.kwaliteitskoepel.nl/kwaliteitsbibliotheek/uit-
gebreid_zoeken/radiotherapie-bij-patienten-met-een-icd-
of-pacemaker.html. During the preparation of this
guideline, the AAPM also recognised the value of renew-
ing the guideline. A new Taskgroup (TG 203) was formed
and it is expected that this guideline will be ready in
2014. One of the authors of the Dutch guideline is also a
member of this AAPM Taskgroup.
Literature review
An overview of some of the important papers on this
topic is presented in Table 1 There still is a paucity of
data and many papers are based on patient case reviews
rather than large cohorts of patients or large numbers of
CIEDs irradiated in vitro.
CIED technology
Modern CIEDs contain Complementary Metal Oxide
Semiconductor (CMOS) technology. The CMOS tech-
nology developed in the early nineties was more radio-
sensitive than the previously used bipolar transistors
(TTL technology) [9]. However, CMOS technology has
rapidly developed and currently is much more radiore-
sistant. It is for example routinely used for aerospace
applications requiring a tolerance up to several thousand
Grays [18]. TTL CIEDs have not been implanted in re-
cent decades so an assumption can be made that
patients with CIEDs no longer carry such a device. Mod-
ern CIEDs, however, are still radiosensitive because of
their increased circuit complexity, the ever decreasing
power consumption and possibly the decreased dose at-
tenuation of the CIED case. The leads are generally con-
sidered to be insensitive to radiation, although one case
report claims irradiation-induced damage of the leads,
leading to an observed shock coil failure [19].
Pacemaker versus ICD
CIED manufacturers have diverging opinions on sensi-
tivity of different CIEDs and advices for the management
of patients with CIEDs during radiotherapy [2]. A guide-
line by Guidant published in 2003 stated that ICDs
might be more sensitive because operating instructions
are stored in RAM memory [20]. In a later (2008) publi-
cation by Boston Scientific (which incorporated Guidant
in 2005) this difference is no longer cited, then stating
that there is no safe lower dose limit and that some
studies consider 2 Gy as the maximum allowable safe
dose to a CIED [21]. CIED manufacturer Medtronic, al-
though no supportive data are reported, claims that the
dose tolerance is 5 Gy for pacemakers and 1–5 Gy for
ICDs with the dose tolerance being specific to the type
of ICD. Medtronic reports minor pacemaker damage
above 5 Gy [22]. St. Jude Medical states the risk of
Table 1 Overview of important in vivo and in vitro studies (with either a large number of CIEDs or interesting findings,
excluding reviews)









Number of defects type of defect
2010 Ferrara Prospective
in vivo
37 8 < 2,5 No defects No defects
2010 Wadasadawala Review+ 8
pacemakers
8 0 60 No defects No defects
2009 Zweng case report 1 0 0.11 1 [1] @ 0.11 Gy runaway PM
2009 Gelblum Retrospective
in vivo
0 33 <3 1 [33] @3 Gy Reset to factory settings
2008 Lau case report 0 1 <0,15 1 [1] @ 0,15 Gy electrical reset










< 4 (in vitro)
unreported
for in vivo
No defects No defects, 4 devices relocated before RT
2008 Munshi [52] case report 1 4.3 No defects No defects
2007 Nemec case report 0 1 < 6 1 [1] @ <1 Gy* Runaway ICD
2005 Hurkmans[24] in vitro
research
19 0 < 120 14[19] @ 120 Gy 1
[19] @ 20 Gy











To low shock energy, sensing and Battery charge
time, erroneous VF or VT detection.
2004 John case report 0 1 50 1 [1] @ not
reported dose
shock impedance (coil failure)
2002 Mouton in vitro
research
96 0 200 4(96) @ 0,2 Gy 21
(96)@2 Gy >0.2 Gy/
min




0 3 < 5 no defects No defects
2000 Tsekos case report 1 0 < 50 1 [1] @ not
reported dose
Decrease of battery load
1994 Souliman in vitro
research
18 0 70 11 [18] @ 7,0 Gy 2
[18] @ 1,7 Gy 5 [18]
@ 2,5 Gy
1) temporary change to interference or safety
mode pacing lasting for the duration of the
irradiation only [2] change to interference mode
pacing—from which recovery may occur after
reprogramming the pacemaker [3] severe damage
1994 Wilm [53] in vitro
research
20 0 300 2 [20] @ 10 Gy
(complete defects)
Complete defect, decrease of pace amplitude, loss
of telemetry
1991 Rodriguez in vitro
research
23 4 < 50 1 [23] @ 14 Gy 11
[23] sensitivity 9
[23] telemetry
sensitivity, telemetry and total defect
* estimated from the case report.
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mulative radiation exposure and that no exact threshold
for damage has been determined; the range has been “as
low as” 20 Gy in some devices and as high as 150 Gy in
others. In a table of defect frequencies, they do not make
a distinction between pacemakers and ICDs [23].
In vitro studies: ICDs in the direct beam
In all 11 ICDs placed in a direct 6 MV beam as stud-
ied by Uiterwaal et al., defects were observed [24].These defects caused loss of pacing or rapid ventricu-
lar pacing, which in patients might lead to ventricular
fibrillation. Four out of 11 ICDs incorrectly detected
ventricular fibrillation or tachycardia, which would
lead to inappropriate therapy, i.e., delivery of a high
voltage shock.
In vitro studies: Electromagnetic interference effects
Electromagnetic interference (EMI) may lead to inappro-
priate sensing of a myocardial potential, resulting in
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ming. These effects are mainly temporary or reversible.
There are no published studies reporting serious problems
near linear accelerators [10]. Electromagnetic fields
around modern linear accelerators have decreased, redu-
cing the concern to patients with a CIED [4,9,24-27].
Therefore, EMI does not seem to be of clinical relevance.
In vitro studies: Dose rate effects
There is to our knowledge only one published study in-
volving dose rate effects on CIEDs [28]. Of the 96 pace-
makers studied, none showed any defects at a dose rate
of 0.2 Gy/min. Only two devices had a defect below 1
Gy/min. Most of the first defects (78 out of 96) were
observed at dose rates of 8 Gy/min or higher. The
authors concluded that one could consider 0.2 Gy/min
as the maximum acceptable dose rate. Some parts of the
CIED, mainly the parts involved in rhythm sensing,
reference voltage and physiologic sensing, are possibly
sensitive to temporary interference from a high dose
rate. This may inadvertently cause an ICD to deliver a
shock, stop pacing, reset itself or display other defects
[29]. The dose rate range currently used for radiother-
apy, including for example flattening filter free beams is
approximately 1–10 Gy/min at isocentre. The dose rate
at the CIED location is generally at least 10 times lower
if the CIED is not located in a direct beam, i.e., lower
than 1 Gy/min. Thus, in general, dose rate effects do not
seem frequent in radiation therapy and, based on the
theoretical failure mechanism, dose rate effects are tem-
porary and reversible [18]. Based on the same theoretical
failure mechanism, the pulse dose rate might actually be
much more important, as CIED effect occurs due to the
radiation-induced photocurrents generated by high dose
rate and begins to be appreciable for dose rates > 104
Gy/sec. In radiation therapy, we are dealing with rela-
tively low radiation pulse dose rates (< 100 Gy/sec) so at
these levels there is no significant dependence on dose
rate [18]. Direct exposure from kV or MV imaging for
treatment field verification occurs at often even lower
dose rates. Although CIED effects have for example been
shown during kV imaging (CT scanning), these effects
were also temporary and reversible [29].
In vitro studies: Cumulative dose and neutron dose
A number of in vitro studies have been published
[18,25,26,28,30,31]. All of these studies show an increase
in defects with an increase in accumulated dose. We
have not found any evidence in the literature that the
fraction size by itself is of clinical importance. Unfortu-
nately, a reliable lower dose threshold at which no
defects occur can not be established using these data be-
cause defects at very low dose levels were reported. Most
probably, effects observed at very low dose levels arecaused by neutrons evoking changes in the memory or
the logical circuits of the CIED [32-35]. The fast and
thermal neutron dose of a 18 MV beam was measured
to be approximately 10–20 times higher than for a 10
MV beam in a setup build to measure the influence of
radiation therapy on CIEDs [35]. Mouton et al. (2002)
reported changes in the output of CIEDs at a cumulative
dose to the CIED of 0.15 Gy in an 18 MV beam. They
also found that cumulatively 6 and 14 of the 96 pace-
makers showed a first, as they stated “important” defect
at 2 Gy and 5 Gy, respectively. These numbers seem
considerable. However, the authors note that some of
the “important” defects reported have no clinical
consequences.
Clinical studies
Only 4 substantially sized in vivo studies have been pub-
lished. Ferrara et al. reported no problems in a cohort of
45 patients with an average maximum CIED dose equal
to 2.5 Gy for patients treated in the head & neck area
and equal to 1.8 Gy for patients treated in the thoracic
area [36]. Kapa et al. reported on 12 patients treated be-
tween 2002 and 2007 [31]. Four patients receiving radio-
therapy for a tonsil tumour or left-sided lung tumour,
had their CIED relocated before treatment. No CIED
problems were observed in any of the reported patients.
In the same paper, they reported that they did not find
any defects during an in vitro study of 20 ICDs irra-
diated to a dose of 4 Gy. Wadasadawala et al. reported
on 8 pacemaker patients receiving a cumulative dose of
0.14-60 Gy to the pacemaker and found no defects with
a median follow-up of 5 months [3]. Gelblum et al.
reported on 33 patients with an ICD, with dose to ICD
ranging from 1 cGy to 300 cGy [37]. One patient experi-
enced a reset of the ICD to its factory setting, being trea-
ted for rectal cancer using 15 MV photon beams. The
report was initiated after they had discovered a similar
reset to factory settings for a patient treated for prostate
cancer using 15 MV photon beams. They suspect both
resets are caused by neutrons. There are numerous case
reports, of which some are included in Table 1 The
details of the radiotherapy and dose levels at which
defects were seen were often not clearly documented in
these studies [19,27,38-40].
Dose calculations and measurements
It is important to realise that dose levels to CIEDs
reported in the literature are predominantly based on
estimated values from simulator or planning data and
not on direct measurements. Moreover, none of the arti-
cles report the use of heterogeneity corrections to cor-
rect for the density of the CIED itself. It is important to
realise that the accuracy of the measurement or calcula-
tion only needs to be high enough to determine in which
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achieve this, the patient should be categorised in the
highest category of the two categories that might be ap-
plicable for that patient. To within a few centimetres
from the field edges, treatment planning systems gener-
ally can be used for this purpose. At a further distance,
Monte Carlo based calculations are a viable tool. How-
ever, such models need to be properly modelled and
validated for this purpose. Instead of calculating the dose
to the CIED, one could consider measuring the dose,
preferably using TLDs or OSLDs. However, accurate
measurement of the dose to the CIED is not always
possible [8].Clinical consequences of CIED malfunction
Consequences of CIED malfunction depend on the spe-
cific type of malfunction and on the pacing dependency
of the patient. As described above, CIED malfunctions
that have been reported are among others loss of pacing,
very rapid pacing and oversensing. A detailed categorisa-
tion of effects is for example given by Hurkmans et al.
[26].Pacing function
CIEDs are implanted for a variety of indications. Pace-
makers are typically implanted for bradycardias whereas
ICDs are implanted in patients with an increased risk of
potentially lethal, ventricular arrhythmias. ICDs have a
pacemaker function as well. Depending on the intrinsic
heart rhythm of the patient and the setting of the pace-
maker function, pacing by the pacemaker or ICD may
occur occasionally or continuously. In a mixed popula-
tion, around 10% (range: 2-63%) of patients are so-called
pacing dependent, meaning they have no intrinsic or es-
cape rhythm and may become symptomatic (syncope,
arrhythmia, serious injury or even sudden death) when
the CIED pacing function fails [41-43]. It is obvious that
a complete loss of pacing ability will have major implica-
tions for pacing dependent patients. If the underlying
heart rhythm is not sufficient, the patient will require
cardiopulmonary resuscitation. Often, this is followed by
external pacing through intravenously placed leads or
external electrodes connected to a temporary external
pacemaker. Other forms of CIED malfunction may also
lead to serious problems for these patients [44]. With
very rapid ventricular pacing, ventricular tachycardia
may occur which can lead to a life threatening decrease
of blood pressure [27]. The patient may experience pal-
pitations, vertigo and/or syncope. If the arrhythmia dete-
riorates into ventricular fibrillation this may lead to the
patient’s death. The same may happen when the shock
function of an ICD is malfunctioning.Tachy-arrhythmia ICD therapy
The nature of ICD therapy is completely different. Prac-
tically all the time, the ICD acts as a watch-dog since
tachycardias that may be terminated by the ICD occur
infrequently. Furthermore, the moment of therapy is un-
predictable. In a group of patients with ischemic cardio-
myopathy in whom an ICD was implanted because of
earlier ventricular arrhythmias, during 8 years follow-up,
47% of patients experienced at least one ventricular
arrhythmia triggering device therapy. When one would
assume that the chance of this therapy is constant, ICD
therapy occurring at least once during a 6 week course
of radiation treatment can be calculated at approxi-
mately 0.7%. Deactivation of the ICD shock function
during the entire radiation therapy period would lead to
a similar chance of withholding a potentially lifesaving
shock. This is an unacceptably high figure and thus, de-
activation of the ICD for an entire course of radiation to
prevent inappropriate ICD therapy in radiotherapy clin-
ical practice is not desirable. In contrast, it is shown
in vitro that an ICD could interpret radiation therapy
induced signals as an arrhythmia which may lead to in-
appropriate shock delivery [25]. Such ICD shocks in
patients are uncomfortable [24,45,46], although not le-
thal. In the ICD population, approximately 10-20% of
patients experience an unnecessary shock within a 5 year
follow-up period. It has been reported that these patients
have a loss in their quality of life and may develop psy-
chological complaints as a result [47]. When possible,
measures should be taken during radiotherapy to pre-
vent an inappropriate shock delivery. This may be
achieved by reprogramming of deactivating the ICD or
applying a heavy magnet (90–130 Gauss). Whether or
not this procedure in itself has an influence on the
patient’s well-being is not known and might be subject
to further study.
Possibility of CIED relocation
In order to avoid radiotherapy related CIED problems,
relocation may be considered. This may be the case
when the CIED is near the volume to be irradiated.
CIEDs are usually implanted in the pectoral area, with
leads leading through a local vein to the heart. Reloca-
tion usually implies explantation of the CIED from the
ipsilateral side and implanting a new CIED, including
new leads, on the contralateral side. Leads at the ipsilat-
eral side would typically be left in place, because of the
risk of lead extraction. According to Dutch guidelines,
lead removal is only performed in specialized centres
with thoracic surgery at hand as 1-2% of patients will ex-
perience serious complications (0.3% mortality) requir-
ing acute thoracic surgery [48].
The risk of CIED re-implantation at the contralateral
side is equivalent to a new CIED implantation. The main
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moval of the device , and pneumothorax (0.8%-1.7%)
[49]. In case of infection, relocation possibilities would
be limited. In case radiotherapy may lead to CIED mal-
function, an elective replacement may be warranted,
which may lead to complications as well. In a large mul-
ticentre study of 2915 patients undergoing ICD replace-
ment, 5.8% experienced a serious complication [50].
Other studies have shown that the chance of infection
increases with subsequent CIED replacement [51].
Patient perspective
It is very important to consider the patients perspective
when decisions regarding the management of their CIED
and treatment plan are being made. Our patient focus
group consisted of 5 patients: 3 receiving treatment for
prostate cancer, one for breast cancer and one for lung
cancer. It was very difficult to even arrange such a small
focus group, as the number of patients alive and willing
to contribute to such a group is inevitably low. They
unanimously considered CIED management problems
related to radiation therapy of low interest as they were
dealing with much more serious health care related pro-
blems. Some appreciated receiving detailed information
whereas others did not wish to be informed. Collectively
they all agreed that the treating radiation oncologist and
cardiologist should together decide and present the best
course of individualised treatment to them. It should be
clear that this group of patients is too small to draw any
hard conclusions. However, we hope it might stimulate a
broader investigation into the expectations and needs of
these patients in regard to this topic.
Patient management
The risk of malfunction generally increases with dose
and malfunction may especially be acutely deleterious in
pacing dependent patients. Therefore, a patient risk cat-
egorisation is proposed incorporating these two para-
meters (Table 2). Sundar et al., [8] suggested a similar
categorisation, making the distinction between pacing
dependent and independent patients.. Our new categor-
isation below 2 Gy is identical to the categorisation pro-
posed by Sundar. Above 2 Gy, Sundar et al. only
categorised the pacing dependent patients. We have also
defined the category of pacing independent patient re-
ceiving a dose of more than 2 Gy and extended theTable 2 Patient risk categories: cumulative dose to the
CIED and pacing independent versus pacing dependent
< 2 Gy 2-10 Gy > 10 Gy
pacing-independent Low risk Medium risk High risk
pacing dependent Medium risk Medium risk High risk
Risk defined from the patients’ perspective; how high is the risk for the
patient? The patient’s risk is not equal to the risk of a CIED defect.classification for both pacing dependent and independ-
ent patients with another dose level (10 Gy). Another
important distinction is their suggestion to pursue alter-
native treatment options or consider relocation of the
CIED for medium and high risk patients. We found the
advantages of these alternatives very often do not out-
weigh the reduction of the chance on potential CIED
problems related to radiotherapy. As there are no ample
data that support deviation from the 2 Gy dose level as
proposed by the AAPM guideline from 1994 to distin-
guish risk categories, we have adopted this level here
too. For the majority of patients the CIED dose will be
lower than 2 Gy. A very small subgroup of around a few
percent of patients with a CIED receiving radiotherapy
in The Netherlands will have an estimated CIED dose
above 10 Gy. Although the chances of malfunction obvi-
ously do not markedly increase above 10 Gy, this limit is
considered to be practical and gives some guidance for
patients which might receive a very high CIED dose.
There was consensus that it would not be needed nor
feasible to either adapt the treatment, relocate the CIED
or ECG monitor all patients that receive a CIED dose of
more than 2 Gy every fraction. On the other hand, we
agreed this approach would be needed for patients re-
ceiving a much higher CIED dose. The limit was chosen
to be 10 Gy rather than a higher value because the num-
ber of patients that will fall in the category of 10 Gy or
higher was deemed manageable. For these patients,
adaptation of the radiation therapy treatment or reloca-
tion of the CIED will often be the best choice. In excep-
tional cases, patients from this subgroup may receive
radiation therapy with the CIED in place. This decision
can only be taken in concordance with the patient and
the treating cardiologist. For patients that will receive an
estimated CIED dose between 2 and 10 Gy, relocation of
the CIED might be considered. However, with some add-
itional safety measures these patients might also receive
radiation therapy.
Prior to radiation therapy
As the specialist that considers referring a patient for
radiotherapy and the treating cardiologist might not be
able to very roughly estimate the possible CIED dose
that can be expected to result from radiotherapy, a fig-
ure has been generated which gives upper limit esti-
mates (Figure 1). If the patient is referred for
radiotherapy, a more accurate estimation of the CIED
dose should be made by the responsible clinical physi-
cist, which may be supported by a measurement or cal-
culation. The accuracy needs to be high enough to
reliably determine the patient risk category. No hetero-
geneity correction for the density of the CIED should be
made, as this has not been done in the vast majority of
articles published about CIED dose in relation to CIED
Inform treating cardiologist and inform patient
Determine patients’ pacing-dependency
If ICD, Inform if anti-tachycardia therapy can be switched of by magnet
If CIED check-up > 3 months ago, plan check-up prior to start of 
radiotherapy
Photon beam energy <10MV
Estimate dose on CIED (seed rawing for indication)
Minimize dose on CIED with treatment plan optimisation
Extra CIED check after last RT fraction by pacemaker








In exceptional cases a decision to
start RT can be made
safety measures which are atleast




CIED checked within 24 hours by
pacemaker technician
INTERMEDIATE RISK
See LOW RISK plus:
Crashcart present during RT
Weekly check-up CIED
Possibility of external pacing
Trained staff with cardiology
expertise can be present within 10
minutes





In case ICD: program




Pacing independent patient and




Patient with CIED and indicated radiotherapy
When the tumour is
within this zone it is





Figure 1 Flow diagram of Dutch guidelines. *Estimation of dose in case of a pectoral placed CIED.
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portant information from their medical file should be
available. Patients should be instructed to report any
temporary or permanent cardiac symptoms that arise.
To establish CIED functionality prior to treatment and
to detect a possible change in the pacing-dependency of
the patient, it is recommended to examine technical
CIED function if this has not been done within the past
3 months (routine CIED checks are usually performed
every 3–6 months). In cases in which radiation treat-
ment is required urgently, a decision regarding the man-
agement of the patient must be made using the available
information. As the risk of CIED malfunction increases
with cumulative dose, the dose to the CIED should be
limited as much as possible during treatment planning.
Beam energies above 10 MV should be avoided due totheir high neutron production, as e.g., already suggested
by Gelblum et al. [37].
During radiation therapy
The intensity of patient monitoring during radiation ther-
apy has been adjusted to the risk of CIED malfunction
and the clinical consequences. For each risk category,
general measures form the baseline standard of care.
General measures
Treating staff should be knowledgeable in the manage-
ment of the patient in case complications to the CIED
occur during treatment. Audiovisual observation of
the patient during radiation is mandatory. In case
CIED malfunction is suspected, the cardiologist and pace-
maker technician need to be consulted and together with
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ical physicist, further management of the patient should
be determined. In case of an emergency caused by a CIED
defect, the standard resuscitation protocol of the institute
should be followed. In case of ICDs, in order to avoid dis-
tress that may be caused by unnecessary ICD shock ther-
apy, this should be deactivated during treatment sessions
through programming or the use of a heavy magnet. If an
intra-cardiac electrogram during the first fraction does not
show aberrations or morphology that would trigger antita-
chycardia therapy, than it might be concluded that the risk
of an inappropriately delivered therapy in subsequent frac-
tions is acceptable. In this case it might be considered to
refrain from deactivating the anti- tachycardia therapy
during subsequent fractions. However, a careful study fol-
lowing every fraction is recommended.
Low risk
The low risk group is the group of patients that receive
a CIED dose below 2 Gy and are not pacing dependent.
No extra measures other than the general measures are
needed for this group.
Medium risk
The medium risk group is the group of patients that re-
ceive a CIED dose of 2 Gy to 10 Gy together with the
group of patients that are pacing dependent and receive
a CIED dose below 2 Gy. By taking appropriate add-
itional safety measures, this group may still be safely
treated. These measures are: weekly CIED check by a
pacemaker technician and adequate equipment present
during each fraction, consisting of ECG-monitor and
‘crash cart’ including defibrillator or AED. Furthermore,
in case of an emergency the following should be avail-
able for the pacing dependent patient: external pacing
equipment (e.g. external pacemaker), personnel trained
in resuscitation and a pacemaker technologist and/or
cardiologist must be able to reach the patient within
10 minutes of a request in case of an emergency.Table 3 Staff and departmental requirements
Low risk
Department - resuscitation protocol
- good consultancy agreement with cardiology /
electrophysiology dept.
Staff - Radiation oncologist and clinical
physicist available with sufficient
knowledge in the management of patients with a CIED.
- Radiation therapy technologists should receive training so the
can manage complications experienced by the CIED patient
having radiation treatmentHigh risk
The high risk group is the group of patients that receive
a CIED dose of 10 Gy or more.
If the CIED dose is estimated to exceed 10 Gy and
CIED relocation or adaptation of the radiation treatment
schedule is not possible, the question should be
answered whether the indications for radiation therapy
outweigh the CIED related risks. If so, individual mea-
sures that are at least equal to the measures of the
medium risk category must be taken. Besides, one can
include ECG-monitoring during each treatment session
with knowledgeable personnel present to interpret the
ECG. The CIED must then be checked within 24 hours
of each treatment session by a pacemaker technician.
After radiation therapy
Several reviews recommend follow-up checks with a car-
diologist because radiotherapy induced CIED defects
may present long after the radiation therapy treatment
course has finished. The standard frequency of CIED
checks is 3–6 months, however we recommend follow-
up in the cardiology department at: one, three and six
months post radiation therapy treatment.
Staff and department requirements
At least one radiation oncologist and clinical physicist
with sufficient CIED knowledge should be available to
ensure the correct and safe management of the patient
about to undergo radiation therapy treatment. Co-
operation with a cardiologist and pacemaker technician
or the cardiology department is necessary as well as suf-
ficient opportunity for ad hoc consultancy. The radiation
therapists should receive specialty training for the man-
agement of CIED patients. They must know the institu-
tion specific guideline for management of patients with
a CIED referred for radiotherapy as well as being able to
recognise and manage CIED related problems. The radi-
ation therapy department is responsible for training the
therapists as well as ensuring the availability of specialtyMedium risk High risk
- see low risk+ - see medium risk+
- Crash cart including ECG monitor and
defibrillator (or AED) available at
treatment unit
- ECG monitoring at every
fraction
-external pacemaker available
- see low risk+ - see medium risk+
- cardiologist/pacemaker
technician should be available within
10 minutes
- trained staff examines
ECG
y if needed - pacemaker technologist to
check CIED weekly
- pacemaker technologist
checks CIED after every
fraction
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radiotherapy the radiation therapist must switch the ICD
antitachycardia therapy off with a heavy magnet (90–130
Gauss) or a properly trained pacemaker technician must
program this function off and on at each fraction.
In conclusion
An evidence based consensus guideline for the manage-
ment of patients with a pacemaker or implantable cardi-
overter defibrillator has been developed. As it takes into
account modern radiotherapy techniques, modern CIED
technology and practical aspects for the management of
these patients, it is expected to find clinical acceptance
outside The Netherlands.
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